Losartan added to β-blockade therapy for aortic root dilation in marfan syndrome

A randomized, open-label pilot study

Hsin Hui Chiu, Mei Hwan Wu, Jou Kou Wang, Chun Wei Lu, Shuenn Nan Chiu, Chun An Chen, Ming Tai Lin, Fu Chang Hu

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

Objective: To assess the tolerability and efficacy of the investigational use of the angiotensin II receptor blocker losartan added to β-blockade (BB) to prevent progressive aortic root dilation in patients with Marfan syndrome (MFS). Patients and Methods: Between May 1, 2007, and September 31, 2011, 28 patients with MFS (11 males [39%]; mean ± SD age, 13.1±6.3 years) with recognized aortic root dilation (z score >2.0) and receiving BB (atenolol or propranolol) treatment were enrolled. They were randomized to receive BB (BB: 13 patients) or β-blockade and losartan (BB-L: 15 patients) for 35 months. Results: In the BB-L group, aortic root dilation was reduced with treatment, and the annual dilation rate of the aortic root was significantly lower than that of the BB group (0.10mm/yr vs 0.89mm/yr; P=.02). The absolute aortic diameters at the sinus of Valsalva, annulus, and sinotubular junction showed similar trends, with a reduced rate of dilation in the BB-L group (P=.02, P=.03, and P=.03, respectively). Five patients (33%) treated with BB-L were noted to have a reduced aortic root diameter. However, the differences between the groups regarding changes in aortic stiffness and cross-sectional compliance were not statistically significant. Conclusion: This randomized, open-label, active controlled trial mostly based on a pediatric population demonstrated for the first time that losartan add-on BB therapy is safe and provides more effective protection to slow the progression of aortic root dilation than does BB treatment alone in patients with MFS.

Original languageEnglish
Pages (from-to)271-276
Number of pages6
JournalMayo Clinic Proceedings
Volume88
Issue number3
DOIs
Publication statusPublished - Mar 2013
Externally publishedYes

Fingerprint

Marfan Syndrome
Losartan
Dilatation
Therapeutics
Sinus of Valsalva
Vascular Stiffness
Atenolol
Angiotensin Receptor Antagonists
Propranolol
Compliance
Pediatrics
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Losartan added to β-blockade therapy for aortic root dilation in marfan syndrome : A randomized, open-label pilot study. / Chiu, Hsin Hui; Wu, Mei Hwan; Wang, Jou Kou; Lu, Chun Wei; Chiu, Shuenn Nan; Chen, Chun An; Lin, Ming Tai; Hu, Fu Chang.

In: Mayo Clinic Proceedings, Vol. 88, No. 3, 03.2013, p. 271-276.

Research output: Contribution to journalArticle

Chiu, Hsin Hui ; Wu, Mei Hwan ; Wang, Jou Kou ; Lu, Chun Wei ; Chiu, Shuenn Nan ; Chen, Chun An ; Lin, Ming Tai ; Hu, Fu Chang. / Losartan added to β-blockade therapy for aortic root dilation in marfan syndrome : A randomized, open-label pilot study. In: Mayo Clinic Proceedings. 2013 ; Vol. 88, No. 3. pp. 271-276.
@article{b1bb74c2e10e4b81aa300cee96ef3df4,
title = "Losartan added to β-blockade therapy for aortic root dilation in marfan syndrome: A randomized, open-label pilot study",
abstract = "Objective: To assess the tolerability and efficacy of the investigational use of the angiotensin II receptor blocker losartan added to β-blockade (BB) to prevent progressive aortic root dilation in patients with Marfan syndrome (MFS). Patients and Methods: Between May 1, 2007, and September 31, 2011, 28 patients with MFS (11 males [39{\%}]; mean ± SD age, 13.1±6.3 years) with recognized aortic root dilation (z score >2.0) and receiving BB (atenolol or propranolol) treatment were enrolled. They were randomized to receive BB (BB: 13 patients) or β-blockade and losartan (BB-L: 15 patients) for 35 months. Results: In the BB-L group, aortic root dilation was reduced with treatment, and the annual dilation rate of the aortic root was significantly lower than that of the BB group (0.10mm/yr vs 0.89mm/yr; P=.02). The absolute aortic diameters at the sinus of Valsalva, annulus, and sinotubular junction showed similar trends, with a reduced rate of dilation in the BB-L group (P=.02, P=.03, and P=.03, respectively). Five patients (33{\%}) treated with BB-L were noted to have a reduced aortic root diameter. However, the differences between the groups regarding changes in aortic stiffness and cross-sectional compliance were not statistically significant. Conclusion: This randomized, open-label, active controlled trial mostly based on a pediatric population demonstrated for the first time that losartan add-on BB therapy is safe and provides more effective protection to slow the progression of aortic root dilation than does BB treatment alone in patients with MFS.",
author = "Chiu, {Hsin Hui} and Wu, {Mei Hwan} and Wang, {Jou Kou} and Lu, {Chun Wei} and Chiu, {Shuenn Nan} and Chen, {Chun An} and Lin, {Ming Tai} and Hu, {Fu Chang}",
year = "2013",
month = "3",
doi = "10.1016/j.mayocp.2012.11.005",
language = "English",
volume = "88",
pages = "271--276",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "3",

}

TY - JOUR

T1 - Losartan added to β-blockade therapy for aortic root dilation in marfan syndrome

T2 - A randomized, open-label pilot study

AU - Chiu, Hsin Hui

AU - Wu, Mei Hwan

AU - Wang, Jou Kou

AU - Lu, Chun Wei

AU - Chiu, Shuenn Nan

AU - Chen, Chun An

AU - Lin, Ming Tai

AU - Hu, Fu Chang

PY - 2013/3

Y1 - 2013/3

N2 - Objective: To assess the tolerability and efficacy of the investigational use of the angiotensin II receptor blocker losartan added to β-blockade (BB) to prevent progressive aortic root dilation in patients with Marfan syndrome (MFS). Patients and Methods: Between May 1, 2007, and September 31, 2011, 28 patients with MFS (11 males [39%]; mean ± SD age, 13.1±6.3 years) with recognized aortic root dilation (z score >2.0) and receiving BB (atenolol or propranolol) treatment were enrolled. They were randomized to receive BB (BB: 13 patients) or β-blockade and losartan (BB-L: 15 patients) for 35 months. Results: In the BB-L group, aortic root dilation was reduced with treatment, and the annual dilation rate of the aortic root was significantly lower than that of the BB group (0.10mm/yr vs 0.89mm/yr; P=.02). The absolute aortic diameters at the sinus of Valsalva, annulus, and sinotubular junction showed similar trends, with a reduced rate of dilation in the BB-L group (P=.02, P=.03, and P=.03, respectively). Five patients (33%) treated with BB-L were noted to have a reduced aortic root diameter. However, the differences between the groups regarding changes in aortic stiffness and cross-sectional compliance were not statistically significant. Conclusion: This randomized, open-label, active controlled trial mostly based on a pediatric population demonstrated for the first time that losartan add-on BB therapy is safe and provides more effective protection to slow the progression of aortic root dilation than does BB treatment alone in patients with MFS.

AB - Objective: To assess the tolerability and efficacy of the investigational use of the angiotensin II receptor blocker losartan added to β-blockade (BB) to prevent progressive aortic root dilation in patients with Marfan syndrome (MFS). Patients and Methods: Between May 1, 2007, and September 31, 2011, 28 patients with MFS (11 males [39%]; mean ± SD age, 13.1±6.3 years) with recognized aortic root dilation (z score >2.0) and receiving BB (atenolol or propranolol) treatment were enrolled. They were randomized to receive BB (BB: 13 patients) or β-blockade and losartan (BB-L: 15 patients) for 35 months. Results: In the BB-L group, aortic root dilation was reduced with treatment, and the annual dilation rate of the aortic root was significantly lower than that of the BB group (0.10mm/yr vs 0.89mm/yr; P=.02). The absolute aortic diameters at the sinus of Valsalva, annulus, and sinotubular junction showed similar trends, with a reduced rate of dilation in the BB-L group (P=.02, P=.03, and P=.03, respectively). Five patients (33%) treated with BB-L were noted to have a reduced aortic root diameter. However, the differences between the groups regarding changes in aortic stiffness and cross-sectional compliance were not statistically significant. Conclusion: This randomized, open-label, active controlled trial mostly based on a pediatric population demonstrated for the first time that losartan add-on BB therapy is safe and provides more effective protection to slow the progression of aortic root dilation than does BB treatment alone in patients with MFS.

UR - http://www.scopus.com/inward/record.url?scp=84876689767&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876689767&partnerID=8YFLogxK

U2 - 10.1016/j.mayocp.2012.11.005

DO - 10.1016/j.mayocp.2012.11.005

M3 - Article

VL - 88

SP - 271

EP - 276

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 3

ER -